HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BAY 86-7548

(68)Ga-bombesin antagonist

Also Known As:

(68)Ga-DOTA-4-amino-1-carboxymethylpiperidine-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2; 68Ga-RM2

Networked: 12 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - BAY 86-7548: 12

Experts

1.	Iagaru, Andrei: 4 articles (12/2022 - 01/2018)
2.	Baratto, Lucia: 3 articles (12/2022 - 01/2020)
3.	Duan, Heying: 3 articles (12/2022 - 01/2020)
4.	Liang, Tie: 2 articles (12/2022 - 01/2022)
5.	Hatami, Negin: 2 articles (01/2022 - 01/2020)
6.	Fernandez, Philippe: 2 articles (09/2019 - 01/2019)
7.	Hindié, Elif: 2 articles (09/2019 - 01/2019)
8.	Morgat, Clément: 2 articles (09/2019 - 01/2019)
9.	Schollhammer, Romain: 2 articles (09/2019 - 01/2019)
10.	Vimont, Delphine: 2 articles (09/2019 - 01/2019)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 01/01/2023 - "A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer." 12/01/2022 - "Correlation of 68Ga-RM2 PET with Postsurgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer." 01/01/2020 - "Physiological 68Ga-RM2 uptake in patients with biochemically recurrent prostate cancer: an atlas of semi-quantitative measurements." 09/01/2019 - " Sixteen men (median age: 74 years, range 50-80 years) with prostate cancer in different stages who had a recent negative (n = 8) or pathologic (n = 8) PSMA PET underwent a subsequent 68Ga-RM2 PET. " 09/01/2019 - "68Ga-PSMA-617 Compared With 68Ga-RM2 and 18F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer."
2.	Neoplasms (Cancer) 01/01/2023 - "In this study, we evaluated a novel approach of using both 68Ga-RM2 and 68Ga-PSMA11 PET/MRI in each patient before and after HIFU to assess the accuracy of target tumor localization and response to treatment. " 01/30/2019 - "These simple, robust kits shall allow hospitals with different generators to participate in clinical studies of 68Ga-RM2 for screening of GRPR-expressing prostate tumors." 01/01/2023 - "Conclusion: 68Ga-PSMA-617 PET/CT is useful to depict higher, more clinically significant ISUP score lesions, and 68Ga-RM2 PET/CT has a higher detection rate for low-ISUP tumors. " 01/01/2023 - "Results: On a lesion-based analysis (including lesions < 0.1 cm3), 68Ga-PSMA-617 PET/CT detected 74.3% (26/35) of all tumor lesions and 68Ga-RM2 PET/CT detected 78.1% (25/32; 1 patient could not be offered 68Ga-RM2 PET/CT). " 01/01/2023 - "Conclusion: This pilot study showed that 68Ga-PSMA11 and 68Ga-RM2 PET/MRI identified the target tumor for HIFU in 100% and 86% of cases, respectively, and accurately verified response to treatment. "
3.	Breast Neoplasms (Breast Cancer) 01/01/2020 - "68Ga-RM2 has been mostly evaluated for PC detection, but it can be used for other tumors overexpressing GRPR such as breast cancer. " 01/01/2019 - "68Ga-RM2 binding and 18F-FDG binding in tumoral zones were measured and compared using tissue micro-imaging with a beta imager on 14 breast cancer samples (10 primaries and 4 associated metastatic lymph nodes). " 01/01/2019 - "Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples."
4.	Infertility (Sterility) 01/30/2019 - "Sterility, apyrogenicity and long term stability of cold kits; in vitro and serum stability of 68Ga-RM2 were investigated. "

Related Drugs and Biologics

1.	Bombesin Receptors (Bombesin Receptor)
2.	gallium 68 PSMA-11
3.	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)
4.	Radiopharmaceuticals
5.	Ligands
6.	Bombesin

Related Therapies and Procedures

1.	Prostatectomy (Retropubic Prostatectomy)
2.	Extracorporeal Shockwave Therapy